A groundbreaking immunotherapy candidate, now in clinical trials, offers a powerful dual response against cancer. This small molecule increases the activity of immune cells while making tumors more susceptible to immune attack. Developed by researchers at the Broad Institute, AbbVie, and Calico Life Sciences, the drug targets proteins that inhibit immune cell activation, enhancing the body's ability to fight cancer. This innovative approach, distinct from existing therapies, could significantly improve treatment outcomes without the need for combination with other drugs. For more details, visit the Broad Institute's announcement.
send comments